EMA - European Medicines Agency is an official public source that HealthSignal monitors for Pharmaceuticals, Medical Devices, Clinical Trials. The most recent updates we have tracked from it are listed below, each normalised into our index and linked back to the original publication on the source's own website.
23 Jul 2026 PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – July 2026 Online Start date: 23 July 2026, 09:30 (CEST) End date: 23 July 2026, 10:30 (CEST)
EMA - European Medicines AgencyReview will assess risk of leukoencephalopathy, a condition affecting the brainEMA’s safety committee (PRAC) has started a review of medicines containing levamisole, authorised in…, Agenda Agenda of the...
EMA - European Medicines AgencyBenefits no longer proven to outweigh risks of treatment
EMA - European Medicines AgencyIllegal medicines marketed as GLP-1 receptor agonists for weight loss and diabetes pose serious risk to health
EMA - European Medicines AgencyPRAC agrees new safety information on desogestrel- and etonogestrel-containing contraceptives and Litfulo, a medicine to treat alopecia areata
EMA - European Medicines AgencyBoard’s decision concludes renewal process
EMA - European Medicines AgencyOutcomes of the Committee for Veterinary Medicinal Products (CVMP) meeting
EMA - European Medicines AgencyReview will assess risk of leukoencephalopathy, a condition affecting the brain
EMA - European Medicines AgencyPhased review has started to accelerate assessment of medicine with potential to address high unmet medical need
EMA - European Medicines Agency